Neurocrine Biosciences (NBIX) EBITDA Margin Growth (1y) (2011 - 2026)
Neurocrine Biosciences (NBIX) EBITDA Margin Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -1,647.00 |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -368.00 |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -17.00 |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | -341.00 |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -634.00 |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | -538.00 |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 40.00 |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Alkermes | 8.07 Bn | 7.41 Bn | 397.90 Mn | -2,010.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -538.00 |
| Mar 31, 2026 | 1,962.00 |
| Dec 31, 2025 | 356.00 |
| Sep 30, 2025 | 52.00 |
| Jun 30, 2025 | -346.00 |
| Mar 31, 2025 | -1,515.00 |
| Dec 31, 2024 | -655.00 |
| Sep 30, 2024 | 124.00 |
| Jun 30, 2024 | 838.00 |
| Mar 31, 2024 | 4,643.00 |
| Dec 31, 2023 | 408.00 |
| Sep 30, 2023 | 567.00 |
| Jun 30, 2023 | -25,724.00 |
| Mar 31, 2023 | -2,816.00 |
| Dec 31, 2022 | 3,673.00 |
| Sep 30, 2022 | 760.00 |
| Jun 30, 2022 | 25,176.00 |
| Mar 31, 2022 | -1,232.00 |
| Dec 31, 2021 | -4,060.00 |
| Sep 30, 2021 | 3,217.00 |